Derfor forventes det ikke, at montelukast markant ændrer metaboliseringen af lægemidler metaboliseret via dette enzym (f. eks. paclitaxel, rosiglitazon og repaglinid).
Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolized by this enzyme (e. g., paclitaxel, rosiglitazone, and repaglinide.)